All In Biotech

Drug Trial Radar · NCT04128696

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

315

Actual

Start

Nov 21, 2019

Primary completion

Apr 27, 2021

Study completion Jun 20, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC).This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 inducible T cell co-stimulatory receptor (ICOS) agonist and pembrolizumab to pembrolizumab plus placebo in participants with programmed death receptor 1-ligand 1 (PD-L1) combined positive score (CPS) \>=1 R/M HNSCC.

Conditions

  • Neoplasms, Head and Neck

Interventions

  • feladilimabDrug

    feladilimab is available as an intravenous infusion.

  • PembrolizumabDrug

    Pembrolizumab is available as an intravenous infusion.

  • PlaceboDrug

    Placebo is available as an intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in the Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 PopulationTime frame: Up to approximately 16 months
  2. OS in the PD-L1 Expression High (CPS ≥20) PopulationTime frame: Up to approximately 16 months
  3. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) in the PD-L1 CPS ≥1 PopulationTime frame: Up to approximately 16 months

Locations

163 sites in 26 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Duarte, California

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    St. Petersburg, Florida

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Chattanooga, Tennessee

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Seattle, Washington

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    San Juan, Argentina

  • GSK Investigational Site

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    La Plata, Buenos Aires, Argentina

  • GSK Investigational Site

    Darlinghurst, Australia

  • GSK Investigational Site

    Blacktown, New South Wales, Australia

  • GSK Investigational Site

    St Leonards, New South Wales, Australia

  • GSK Investigational Site

    Herston, Queensland, Australia

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Belo Horizonte, Minas Gerais, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Vitória, Espírito Santo, Brazil

  • GSK Investigational Site

    Florianópolis, Santa Catarina, Brazil

  • GSK Investigational Site

    Barretos, São Paulo, Brazil

  • GSK Investigational Site

    São José do Rio Preto, São Paulo, Brazil

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Hamilton, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Rimouski, Quebec, Canada

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.